Warfarin Dosing Biomarkers Could Be Model For Genetic Tests In Labeling
Executive Summary
The development of standards for a warfarin dosing biomarker under a collaboration with the C-Path Institute could pave the regulatory pathway for markers involving other therapeutic agents
You may also be interested in...
Warfarin Label Change Falls Short of Recommending Genetic Testing
FDA took warfarin one step into the world of personalized medicine Aug. 16 with labeling changes that inform patients and doctors about the usefulness of genetic testing before beginning therapy with the blood thinner
Warfarin Label Change Falls Short of Recommending Genetic Testing
FDA took warfarin one step into the world of personalized medicine Aug. 16 with labeling changes that inform patients and doctors about the usefulness of genetic testing before beginning therapy with the blood thinner
Phase III Could Be Replaced With “Targeted Approval” – Manhattan Institute
The need for Phase III clinical trials would be reduced if sponsors use validated biomarkers in Phase II studies under a Manhattan Institute proposal